Author/Authors :
Farhoudi Ramin نويسنده Department of Laboratory Animal Science, Pasteur Institute of Iran, Tehran, IR Iran , Nouri Hamid Reza نويسنده Department of Immunology and Microbiology, Babol University of Medical Sciences, Babol, IR Iran Nouri Hamid Reza , Mahdavi Mehdi نويسنده Department of Immunology, Pasteur Institute of Iran, Tehran, Iran , Yazdi Mohammad Hossein نويسنده Department of Pathobiology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran Yazdi Mohammad Hossein , Nejati Shima نويسنده Infectious Diseases and Tropical Medicine Research Center,
Babol University of Medical Sciences, Babol, Iran , Mirzaee Sahar نويسنده Department of Biotechnology, Faculty of Advanced Sciences
and Technology, Pharmaceutical Sciences Branch, Islamic Azad
University, Tehran, Iran (IAUPS) , Namvar Nabi Allah نويسنده Laboratory Animal Science Department, Pasteur Institute of
Iran, Karaj, Iran
Abstract :
Background Hepatitis B virus (HBV) can cause cirrhosis of the
liver and hepatocellular carcinoma. Due to the lack of sufficient immune
response in whole population, several studies have been conducted to
improve the efficacy of alum- based HBV vaccine. Here, naloxone/alum
mixture as adjuvant was used for the hepatitis B
surface antigen HBsAg vaccine and immune parameters evaluated
in immunized mice. Objectives The present study aimed at investigating
the effect of naloxone/alum mixture for the HBsAg vaccine and comparing
to Fendrix vaccine. Methods Female Balb/c mice were vaccinated at day 0,
14, and 28 with alum- based vaccine or naloxone/alum mixture vaccine in
different doses. Naloxone/alum vaccine groups received a dose of 3, 6,
or 10 mg/kg of naloxone (NLX) in the vaccine formulation. One group
received routine HBsAg alum vaccine and another group received Fendrix
vaccine. Some groups received naloxone plus HBsAg without alum and a
group received HBsAg without adjuvant. Phosphate buffered saline (PBS),
naloxone, and alum were also injected into the control groups
separately. Finally, the naloxone/alum formulated vaccine was compared
with the Fendrix and routine alum- based vaccine with respect to the
levels of total anti-HBS antibody, IFN-γ, IL-4, IgG1, IgG2a, and the
level of lymphocyte proliferation. Results The level of total anti-HBS
antibody in naloxone formulated vaccine was comparable with Fendrix.
Meanwhile, IFN-γ/IL-4 ratio level was significantly higher in naloxone
formulated vaccine groups versus mere vaccine group. IgG2a was also
higher in the naloxone formulated vaccine groups. Conclusions Based on
the data presented in the present study, it was found that naloxone/alum
mixture has the ability to shift the immune response towards Th1 pattern
and potentially increase immunity against infections.
